FDA, PhRMA Liver Toxicity Meeting Will Consider Postmarketing Surveillance
Executive Summary
FDA and the Pharmaceutical Research & Manufacturers of America will discuss new mechanisms for detecting liver toxicity during postmarketing surveillance at a joint workshop on drug-induced liver injury Feb. 12-13.
You may also be interested in...
Barr Fluoxetine Goal: 80% Generic Penetration In First Six Months
Barr hopes to achieve 80% generic substitution for Lilly's Prozac within the first six months after launch of its generic 20 mg fluoxetine capsules.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011